{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:55:18Z","timestamp":1761710118651},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T00:00:00Z","timestamp":1713657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.urology.2024.04.028","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T02:43:52Z","timestamp":1714013032000},"page":"131-137","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Nutritional Supplement With Fermented Soy in Men With an Elevated Risk of Prostate Cancer and Negative Prostate Biopsies: General and Oncological Results From the Prospective PRAECAP Trial"],"prefix":"10.1016","volume":"188","author":[{"given":"Hans","family":"Van Der Eecken","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bram","family":"Vansevenant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ga\u00ebtan","family":"Devos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduard","family":"Roussel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Giesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen","family":"Darras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filip","family":"Ameye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lodewijk","family":"Van Wynsberge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lieven","family":"Goeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Claessens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dieter","family":"Ost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Joniau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2024.04.028_bib1","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1001\/jama.2015.14905","article-title":"Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations","volume":"314","author":"Jemal","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2024.04.028_bib2","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/jnci\/94.13.958","article-title":"Understanding and appreciating overdiagnosis in the PSA era","volume":"94","author":"Yao","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urology.2024.04.028_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta24370","article-title":"Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT","volume":"24","author":"Hamdy","year":"2020","journal-title":"Health Technol Assess (Rockv)"},{"key":"10.1016\/j.urology.2024.04.028_bib4","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3322\/CA.2008.0002","article-title":"Management of complications of prostate cancer treatment","volume":"58","author":"Michaelson","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urology.2024.04.028_bib5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2024.04.028_bib6","doi-asserted-by":"crossref","first-page":"5923","DOI":"10.1200\/JCO.2008.16.8807","article-title":"Plasma isoflavones and subsequent risk of prostate cancer in a nested case-control study: the Japan Public Health Center","volume":"26","author":"Kurahashi","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2024.04.028_bib7","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1159\/000019912","article-title":"Diet and its preventive role in prostatic disease","volume":"35","author":"Denis","year":"1999","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2024.04.028_bib8","doi-asserted-by":"crossref","first-page":"E119","DOI":"10.1111\/bju.12435","article-title":"Soy and soy isoflavones in prostate cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"113","author":"Van Die","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2024.04.028_bib9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/cncr.33875","article-title":"Risk of prostate cancer for men with prior negative biopsies undergoing magnetic resonance imaging compared with biopsy-naive men: a prospective evaluation of the PLUM cohort","volume":"128","author":"Patel","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2024.04.028_bib10","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.urology.2007.02.063","article-title":"Effect of nutritional supplement challenge in patients with isolated high-grade prostatic intraepithelial neoplasia","volume":"69","author":"Joniau","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.urology.2024.04.028_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/nu15234856","article-title":"The use of soy isoflavones in the treatment of prostate cancer: a focus on the cellular effects","volume":"15","author":"Van der Eecken","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.urology.2024.04.028_bib12","first-page":"3577","article-title":"The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones","volume":"132","author":"Setchell","year":"2002"},{"key":"10.1016\/j.urology.2024.04.028_bib13","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1159\/000499246","article-title":"Prostate-specific antigen modulatory effect of a fermented soy supplement for patients with an elevated risk of prostate cancer: a non-randomized, retrospective observational registration","volume":"14","author":"Battaglia","year":"2020","journal-title":"Curr Urol"},{"key":"10.1016\/j.urology.2024.04.028_bib14","first-page":"387","article-title":"How does symptom severity impact clinical outcomes of men with lower urinary tract symptoms after holmium laser enucleation or transurethral resection of the prostate? Cent European","volume":"75","author":"Tamalunas","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2024.04.028_bib15","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/pros.10137","article-title":"Soy isoflavonoid equol modulates the growth of benign and malignant prostatic epithelial cells in vitro","volume":"54","author":"Hedlund","year":"2003","journal-title":"Prostate"},{"key":"10.1016\/j.urology.2024.04.028_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/01635580701267677","article-title":"Review of the factors affecting bioavailability of soy isoflavones in humans","volume":"57","author":"Nielsen","year":"2007","journal-title":"Nutr Cancer"},{"key":"10.1016\/j.urology.2024.04.028_bib17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.steroids.2014.06.012","article-title":"Estrogen receptors alpha (ER\u03b1) and beta (ER\u03b2): subtype-selective ligands and clinical potential","volume":"90","author":"Paterni","year":"2014","journal-title":"Steroids"},{"key":"10.1016\/j.urology.2024.04.028_bib18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/pros.2990210107","article-title":"Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP","volume":"21","author":"Montgomery","year":"1992","journal-title":"Prostate"},{"key":"10.1016\/j.urology.2024.04.028_bib19","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1095\/biolreprod.103.023713","article-title":"Equol is a novel anti-androgen that inhibits prostate growth and hormone feedback","volume":"70","author":"Lund","year":"2004","journal-title":"Biol Reprod"},{"key":"10.1016\/j.urology.2024.04.028_bib20","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/cas.12948","article-title":"Equol inhibits prostate cancer growth through degradation of androgen receptor by S-phase kinase-associated protein 2","volume":"107","author":"Itsumi","year":"2016","journal-title":"Cancer Sci"},{"key":"10.1016\/j.urology.2024.04.028_bib21","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jsbmb.2013.12.010","article-title":"Soy isoflavones and prostate cancer: a review of molecular mechanisms","volume":"140","author":"Mahmoud","year":"2014","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.urology.2024.04.028_bib22","first-page":"989","article-title":"Over 3 decades of research on dietary flavonoid antioxidants and cancer prevention: what have we achieved?","volume":"18","author":"Alfa","year":"2019","journal-title":"Phytochem\u00a0Rev"},{"key":"10.1016\/j.urology.2024.04.028_bib23","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11934-005-0029-y","article-title":"Prostatitis and serum prostate-specific antigen","volume":"6","author":"Sindhwani","year":"2005","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.urology.2024.04.028_bib24","doi-asserted-by":"crossref","first-page":"556","DOI":"10.4161\/cbt.1.5.222","article-title":"IL-10\/IL-10 receptor signaling regulates TIMP-1 expression in primary human prostate tumor lines","volume":"1","author":"Wang","year":"2002","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.urology.2024.04.028_bib25","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jpba.2009.03.028","article-title":"Isoflavone effect on gene expression profile and biomarkers of inflammation","volume":"51","author":"Blay","year":"2010","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.urology.2024.04.028_bib26","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3349\/ymj.2018.59.2.219","article-title":"Prostate-specific antigen kinetics following 5\u03b1-reductase inhibitor treatment may be a useful indicator for repeat prostate biopsy","volume":"59","author":"Heo","year":"2018","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.urology.2024.04.028_bib27","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/jamaoncol.2022.1501","article-title":"Association of 5\u03b1-reductase inhibitors with prostate cancer mortality","volume":"8","author":"Bj\u00f6rnebo","year":"2022","journal-title":"JAMA Oncol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429524003005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429524003005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T05:46:56Z","timestamp":1718948816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429524003005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":27,"alternative-id":["S0090429524003005"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2024.04.028","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nutritional Supplement With Fermented Soy in Men With an Elevated Risk of Prostate Cancer and Negative Prostate Biopsies: General and Oncological Results From the Prospective PRAECAP Trial","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2024.04.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}